Understanding Whole Cell Protein Trafficking In Plasmodium Parasites
Funder
National Health and Medical Research Council
Funding Amount
$466,492.00
Summary
I am a molecular biologist and bioinformatician studying the cell biology of human parasites. I have expertise in the bioinformatic analysis of parasite genomes to predict where proteins will reside in cell, how they participate in metabolic pathways, and how they might be suitable as targets for drugs and vaccines to control parasitic diseases. This fellowship will investigate the cell biology of Plasmodium parasites, the causative agents of malaria, using computational and biochemical tools to ....I am a molecular biologist and bioinformatician studying the cell biology of human parasites. I have expertise in the bioinformatic analysis of parasite genomes to predict where proteins will reside in cell, how they participate in metabolic pathways, and how they might be suitable as targets for drugs and vaccines to control parasitic diseases. This fellowship will investigate the cell biology of Plasmodium parasites, the causative agents of malaria, using computational and biochemical tools to characterise drug and vaccine targets.Read moreRead less
Genomic-based Tools To Support The Control Of Urogenital Schistosomiasis And Hepatic Opisthorchiasis
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Over 100 million people are affected by parasitic flukes that promote malignant tumours. Parasite control depends on a single drug, making resistance an imminent threat. I will deliver new genomic tools to unravel the complex interactions between parasites and humans, and explore parasite population diversity on a continental scale. I will then prioritise a panel of anti-parasitic drug targets and vaccine candidates to deliver the next generation of interventions against parasitic diseases.
Genome-based Tools To Support Urogenital Schistosomiasis Control
Funder
National Health and Medical Research Council
Funding Amount
$429,644.00
Summary
More than 100 million sub-Saharan Africans have urogenital schistosomiasis, a disease that promotes malignant cancer and HIV/AIDS. Control depends on a single drug, making resistance an imminent threat. We will deliver new molecular tools to assess parasite genetic diversity and to prioritise a panel of anti-parasitic drug targets and vaccine candidates. These outcomes will deliver the next generation of interventions against urogenital schistosomiasis.
Comparative And Evolutionary Genomics Of Schistosomes –Identifying Genes Associated With Parasitism, And Novel Drug And Vaccine Targets
Funder
National Health and Medical Research Council
Funding Amount
$352,229.00
Summary
Schistosomiasis remains an important cause of human illness and death globally. My project proposes comparative genomics and evolutionary analysis of recently sequenced schistosome taxa and all publicly available flatworm genomes. The study will provide novel insights into identifying gene functions and pathways important for the parasite-host interaction, reveal novel candidate anti-schistosome drug or vaccine targets, and identify genes associated with bladder tumorogenesis in S. haematobium.
Compounded by massive global food and water shortages, neglected tropical disease (NTD) pathogens have a devastating and long-term impact on billions of humans worldwide. Unlocking the fundamental molecular biology of these pathogens, particularly carcinogens, employing a raft of Frontier Technologies, will lead to new ways of controlling NTDs and will have substantial outcomes through the development of new drugs, vaccines and/or diagnostic tests. We will use cutting-edge molecular technologies ....Compounded by massive global food and water shortages, neglected tropical disease (NTD) pathogens have a devastating and long-term impact on billions of humans worldwide. Unlocking the fundamental molecular biology of these pathogens, particularly carcinogens, employing a raft of Frontier Technologies, will lead to new ways of controlling NTDs and will have substantial outcomes through the development of new drugs, vaccines and/or diagnostic tests. We will use cutting-edge molecular technologies to tackle this area head-on.Read moreRead less
Malaria: From Target Identification And Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$5,276,440.00
Summary
The team brings together a number of experts in various aspects of malaria, vaccines and drug design to develop new therapeutic approaches to control of one of the world�s major infectious diseases. Recent developments such as the complete sequence of every malaria gene provides an unparalleled opportunity to use a number of powerful new techniques in biology to identify vulnerabilities in the parasite that may be targeted. Members of the team include Professor von Itzstein who was responsible f ....The team brings together a number of experts in various aspects of malaria, vaccines and drug design to develop new therapeutic approaches to control of one of the world�s major infectious diseases. Recent developments such as the complete sequence of every malaria gene provides an unparalleled opportunity to use a number of powerful new techniques in biology to identify vulnerabilities in the parasite that may be targeted. Members of the team include Professor von Itzstein who was responsible for the design of the anti-flu drug Relenza, Professor Ross Coppel who is a pioneer in the application of molecular biology to the study of malaria, and Drs Cooke and Plebanski, exciting and talented young scientists who already have made highly significant and important contributions to our understanding of how malaria parasites function and cause disease. Success in this research program has the capacity to save millions of lives each year by preventing the deadly toll of this important human scourge.Read moreRead less
Insights Into The Biology Of The Carcinogenic Blood Fluke, Schistosoma Haematobium – A First Response To The Wake-up Call
Funder
National Health and Medical Research Council
Funding Amount
$307,946.00
Summary
Schistosoma haematobium is a seriously neglected parasite that infects > 100 million people. Chronic infection severely affects the urino-genital system and causes malignant bladder cancer. Advanced technologies will be used to explore, for the first time, the molecular biology of this parasite, design new strategies to fight this insidious pathogen and understand how it induces cancer.
Apical Membrane Proteins As Targets For A Schistosomiasis Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$480,459.00
Summary
Schsitosomiasis is a chronic neglected tropical disease for which there is currently no vaccine. A vaccine is sorely needed to control this parasite. This proposal seeks to identify molecules from the outer surface of the parasite which are recognised by the immune system of people from Brazil who are resistant to schistosomiasis. Molecules identified in this manner will be tested as vaccines in an animal model of schistosomiasis, and ranked based on their performances to enter human trials.
Transcriptome Profiling Of The Human Pathogen Schistosoma Japonicum
Funder
National Health and Medical Research Council
Funding Amount
$257,560.00
Summary
The parasitic disease, schistosomiasis, caused by human bloodflukes of the genus Schistosoma, is a major public health issue in Africa, Latin America and South East Asia. Current control methods are far from ideal, and a comprehensive understanding of the genetic mechanisms which allow schistosomes to grow, develop and survive within their hosts affords the best prospect for identifying new drug and vaccine targets. Microarray technology allows simultaneous monitoring of thousands of different g ....The parasitic disease, schistosomiasis, caused by human bloodflukes of the genus Schistosoma, is a major public health issue in Africa, Latin America and South East Asia. Current control methods are far from ideal, and a comprehensive understanding of the genetic mechanisms which allow schistosomes to grow, develop and survive within their hosts affords the best prospect for identifying new drug and vaccine targets. Microarray technology allows simultaneous monitoring of thousands of different genes, and to determine where and when they are active, thus placing the mass of data generated by genome sequencing programs into a biological and functional context. Microarrays provide a unique, cutting-edge, tool for investigating schistosome biology. We have fabricated a microarray representing some 20,000 schistosome genes. We will use this resource to perform large scale monitoring of schistosome gene expression during the parasite's complex life cycle, targetting the regionally important Asian schistosome, Schistosoma japonicum, for study. This will provide the single largest insight into the genetic changes that occur during schistosome development, will greatly further our understanding of the adaptations needed for the growth, development and survival of the parasite, and will identify genes involved in key biological processes, all of which may be exploitable for future interventions and treatments.Read moreRead less